HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (422)	10/3/2002 9:44:53 PM
From: Miljenko Zuanic	Read Replies (1) of 1022

<I don't have an answer to the question - not that it doesn't worry me... I do have a lot more CAT than ABGX. As regards getting MABs into the clinic, is it possible that the current environment is making companies overcautious about committing to trials ?>> IMW, two main factors for fewer(than expected) MAb entering clinical trials are: 1. Target validation issue, mostly they are interacting with new target without prove that targets are relevant, and 2. Manufacturing issue, shortage of the capacity and experienced teams that can produce sufficient quantity. Rick is correct RE: "if you're trying to block the FUNCTION of a protein..... the portions of molecules that are involved in function are (generalizing) those that are most highly conserved." However, sometimes binding to non-functional epitope (which are less conserved from mice to humans) disrupt ligand-receptor 3D-contact area. Sufficiently to block protein-protein signals. I think that ABX-EGF explored this approach. So, I will continue to believe that HuMAb based drugs will continue to be viable approach, specially when protein-protein interaction are too complex to be targeted with small molecules. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next